findmyKOL

Manish Shah, MD

Enriched profile

Director, Gastrointestinal Oncology Program, Weill Cornell Medicine; Chief, Solid Tumor Service, NewYork-Presbyterian Hospital; Bartlett Family Professor in Gastrointestinal Oncology; Professor of Medicine, Weill Cornell Medical College · Weill Cornell Medicine

ORCID↗NPI↗
✓ Full profile
Region🇺🇸 New York, NY · Northeast · United StatesSpecialtyMedical OncologyFocusGastric Cancer Management and Outcomes+4
Active KOLfindmyKOL type: NationalLatest publication2026Online presenceverified 2026Payments2021–2025NIH funding2006–2026

Manish Shah is Director, Gastrointestinal Oncology Program, Weill Cornell Medicine; Chief, Solid Tumor Service, NewYork-Presbyterian Hospital; Bartlett Family Professor in Gastrointestinal Oncology; Professor of Medicine, Weill Cornell Medical College at Weill Cornell Medicine. OpenAlex indexes 662 publications with 34,069 citations (h-index 83); ClinicalTrials.gov lists 21 registered studies with this person as an investigator.

Data verified 17 Aug 2026

Overview

Updated 15 Oct 2026

Manish A. Shah, MD, is Director, Gastrointestinal Oncology Program, Weill Cornell Medicine. The public record shows 662 publications with 34,069 citations (h-index 83), centered on Gastric Cancer Management and Outcomes, Esophageal Cancer Research and Treatment, Colorectal Cancer Treatments and Studies. It also documents an investigator role on 21 registered clinical trials, industry payments reported by 32 companies, 8 NIH-funded awards (2006–2026).

  • Most recent indexed publication: 2026 · Science advances
  • Top research focus: Gastric Cancer Management and Outcomes
  • 21 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 32 companies

Generated from the cited public record · current as of 15 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Gastroesophageal Cancer10 trialsStomach Neoplasms5 trialsEsophageal Neoplasms4 trialsColorectal Cancer3 trialsRectal Neoplasms3 trialsBacterial Infections1 trialWounds and Injuries1 trialBrain Injuries, Traumatic1 trialLung Cancer (NSCLC/SCLC)1 trialPancreatic Cancer1 trialNeoplasm Metastasis1 trialHydrocephalus1 trial

Research focus

OpenAlex concept fingerprint
Gastric Cancer Management and OutcomesEsophageal Cancer Research and TreatmentColorectal Cancer Treatments and StudiesCancer Immunotherapy and BiomarkersGastrointestinal Tumor Research and Treatment

Drugs & molecules

across trials, industry payments and publications
Keytrudageneric · PembrolizumabClinical trials—Industry payments19Publications8Opdivogeneric · NivolumabClinical trials—Industry payments8Publications2Vyloygeneric · ZolbetuximabClinical trials—Industry payments4Publications5Avastingeneric · BevacizumabClinical trials—Industry payments1Publications3Lenvimageneric · LenvatinibClinical trials—Industry payments3Publications1Onivydegeneric · IrinotecanClinical trials—Industry payments3Publications1Fruzaqlageneric · FruquintinibClinical trials—Industry payments9Publications—Wegovygeneric · SemaglutideClinical trials—Industry payments7Publications—Lutatherageneric · DotatateClinical trials—Industry payments5Publications—Tevimbrageneric · TislelizumabClinical trials—Industry payments4Publications—Braftovigeneric · EncorafenibClinical trials—Industry payments3Publications—Creongeneric · Amylase / lipase / proteaseClinical trials—Industry payments2Publications—

Works with

trial sponsors and companies reporting payments
E.R. Squibb & Sons, L.L.C.Clinical trials—Industry payments22AstraZeneca Pharmaceuticals LPClinical trials—Industry payments21Merck Sharp & Dohme LLCClinical trials—Industry payments19Genzyme CorporationClinical trials—Industry payments12Merck Sharp & Dohme CorporationClinical trials—Industry payments12Weill Medical College of Cornell UniversityClinical trials11Industry payments—Takeda Pharmaceuticals U.S.A., Inc.Clinical trials—Industry payments9Novo Nordisk IncClinical trials—Industry payments7Novartis Pharmaceuticals CorporationClinical trials—Industry payments6Astellas Pharma US IncClinical trials—Industry payments5AstraZeneca UK LimitedClinical trials—Industry payments4BeiGene USA, Inc.Clinical trials—Industry payments4Abbvie Inc.Clinical trials—Industry payments3Array Biopharma IncClinical trials—Industry payments3Coherus Biosciences Inc.Clinical trials—Industry payments3Gilead Sciences, Inc.Clinical trials—Industry payments3Ipsen Biopharmaceuticals, IncClinical trials—Industry payments3Regeneron Pharmaceuticals, Inc.Clinical trials—Industry payments3Alliance for Clinical Trials in OncologyClinical trials2Industry payments—Eisai Inc.Clinical trials—Industry payments2Memorial Sloan Kettering Cancer CenterClinical trials2Industry payments—Amgen Inc.Clinical trials—Industry payments1Boehringer Ingelheim International GmbHClinical trials—Industry payments1Boehringer Ingelheim Pharmaceuticals, Inc.Clinical trials—Industry payments1Boehringer Ingelheim RCV GmbH & Co KGClinical trials—Industry payments1BPGbioClinical trials1Industry payments—Bristol-Myers SquibbClinical trials1Industry payments—Brown UniversityClinical trials1Industry payments—Eli Lilly and CompanyClinical trials—Industry payments1EMD Serono, Inc.Clinical trials—Industry payments1

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
662publications

Distinct works indexed by OpenAlex, matched via ORCID; 35 in PubMed.

34,069citations

Total citations across indexed works.

83h-index

Hirsch index (OpenAlex). i10-index 232.

Clinical & industry

trials, payments and federal funding
21clinical trials

Investigator role on registered studies.

View trials ↓
32companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
8NIH grants · 2006–2026

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 15 Oct 2026

Listed as an investigator on 21 registered studies on ClinicalTrials.gov. The most recent:

All 21 trial records: search, sort and filter.Explore →

Industry payments

Updated 15 Oct 2026

32 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

All 48 payment records: search, sort and filter.Explore →
View the CMS Open Payments record ↗

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    80.4%
    Platinum-based Drug70.7%
    Oxaliplatin100%
    Part B, office-administered≥22 patients
    Nucleoside Metabolic Inhibitor7.2%
    Fluorouracil62%Gemcitabine hydrochloride39%
    Part B, office-administered≥32 patients

    + 1 more class in this area

  • Metabolism & gastrointestinal

    14.1%
    Anticholinergic7.6%
    Atropine sulfate100%
    Part B, office-administered≥13 patients
    Serotonin-3 Receptor Antagonist6.5%
    Palonosetron hcl100%
    Part B, office-administered≥37 patients

  • Sensory organs

    3%
    Corticosteroid3%
    Dexamethasone sodium phosphate100%
    Part B, office-administered≥25 patients
All 4 therapeutic areas: search, sort and filter.Explore →
Where care is delivered (Part B)0.2% facility · 99.8% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 15 Oct 2026

8 NIH research awards on record, funded 2006–2026 per NIH RePORTER. The latest:

All 68 award records: search, sort and filter.Explore →

Congress activity

Updated 15 Oct 2026

174 congress contributions (2004–2026) across AACR, ASCO, ASH, ENDO, ESMO per OpenAlex. The most recent:

All 174 congress records: search, sort and filter.Explore →

Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.

Publications

Updated 15 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

All 35 publications: search, sort and filter.Explore →

Most-cited works

by citation count (OpenAlex)
  1. 01
    A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.
    Article3,069 citations1993
    openalex.org ↗
  2. 02
    Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer
    Article1,822 citations2018
    doi.org ↗
  3. 03
    Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
    Article1,615 citations2021
    doi.org ↗
  4. 04
    Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
    Article1,187 citations2020
    doi.org ↗
  5. 05
    Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
    Article1,109 citations2011
    doi.org ↗
All 662 cited works: search, sort and filter.Explore →

Network

Updated 15 Oct 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Eric Van Cutsem65David P. Kelsen64Kohei Shitara61David H. Ilson54Allyson J. Ocean54Florian Lordick51Yung‐Jue Bang48Jean‐Philippe Metges48Peter C. Enzinger47Doron Betel46Rui‐Hua Xu45Prashant V. Thakkar44Zev A. Wainberg41Alexander Starodub39Gary K. Schwartz36Paraskevi Giannakakou35Kei Muro35Laura H. Tang34Niall C. Tebbutt33Heinz‐Josef Lenz32Giuseppe Galletti32Michael A. Kiebish31Leonardo O. Rodrigues31Niven R. Narain31Rangaprasad Sarangarajan31Vivek K. Vishnudas31Janice R. Stevens31Ralph Zinner31Toshihiko Doi30Ely Benaim30Eileen M. O’Reilly30Keun‐Wook Lee30Daniel G. Coit29Vivek Subbiah29Mithat Gönen29Gregory M. Miller29Lin Shen29Viatcheslav R. Akmaev29Allison Klotz28Madappa N. Kundranda28

Online presence

Updated 15 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/manish-shah-md-9339551b

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
  • Doximity

    doximity.com/pub/manish-shah-md-d8c75aa7

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
  • LinkedIn

    linkedin.com/in/manish-shah-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗

Mentions by others

where others cite or feature them
  • Spotify

    open.spotify.com/show/6MQnPwZIXJHrCVBBxhTt37

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →open.spotify.com ↗
  • YouTube

    youtube.com/playlist

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 15 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • MD

    Harvard Medical School/MIT Health Sciences and Technology Program

    1996
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →weillcornell.org ↗
  • BSE

    Biomedical Engineering, Johns Hopkins University

    1991
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →weillcornell.org ↗
  • Board Certified

    Internal Medicine, American Board of Internal Medicine

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →weillcornell.org ↗
  • Board Certified

    Medical Oncology, American Board of Internal Medicine

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →weillcornell.org ↗

Editorial & leadership roles

journal and society appointments
  • Expert Panel Co-Chair

    ASCO Guideline: Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer

    2026
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
  • Guideline Co-Chair

    ASCO Treatment of Locally Advanced Esophageal Carcinoma Guideline and Rapid Recommendation Update

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopubs.org ↗
  • Gastrointestinal Disease Section Editor

    journal Cancer

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncodaily.com ↗
  • Fellow of the American Society of Clinical Oncology (FASCO)
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
  • Chair

    Scientific Advisory Board, DeGregorio Family Foundation for Stomach and Esophageal Cancer Education and Research

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →weillcornell.org ↗
  • NIH/NCI Study Section Member
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →weillcornell.org ↗
  • Case Series Editor

    Management of Complex Cases in GI Oncology, Journal of Gastrointestinal Oncology

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →weillcornell.org ↗

Awards & honors

honors on the public record

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.